Abstract
Background
S-l is a newly developed novel oral dihydrouracil dehydrogenase inhibiting fluoro-pyrimidine drug consisting of 1 M tegafur (FT), 0.4 M 5-chloro-2, 4-dihydroxypyrimidine (gimeracil), and 1 M potassium oxonate (oteracil), with efficient antitumor activity and low gastrointestinal toxicity which is widely used in Japan against advanced gastric, head and neck cancers. We investigated its clinical efficacy against metastatic breast cancer.
Methods
A non-blind phase II study was carried out to evaluate the efficacy and toxicity in metastatic breast cancer patients. Patients with measurable metastasis foci (n = 111) were enrolled, and 108 patients were regarded as eligible. S-l was administered orally at a standard dose of 80 mg/m2/day b.i.d. One course consisted of 28 consecutive days of administration followed by a 14-day rest, and courses were repeated up to six times.
Results
Among the eligible patients, 10 had a complete response and 35 had a partial response, with an overall response rate (CRplus PR) of 41.7% (95% confidence interval: CI, 32.3–51.5%). The incidences of toxicity (≧ grade 3) were neutropenia 9.1%, anemia 0.9%, anorexia 3.6%, stomatitis 1.8%, nausea/vomiting 1.8%, diarrhea 0.9%, and fatigue 2.7%, however no treatment-related deaths were observed. The median survival time was 872 days (95% CI, 572-1,110 days). There was no difference in response rate or toxicity between the under 65-year-old group and the older group.
Conclusion
S-l was demonstrated to have high efficacy with low gastrointestinal toxicity even in older patients and will be a promising new chemotherapy drug for metastatic breast cancer.
Similar content being viewed by others
Abbreviations
- CI:
-
Confidence interval
- CR:
-
Complete response
- CVI:
-
Continuous venous infusion
- DPD:
-
Dihydropyrimidine dehydrogenase
- DIF:
-
DPD-inhibitory fluoropyrimidine
- FT:
-
Tegafur
- 5-FU:
-
5-Fluorouracil
- MST:
-
Median survival time
- NC:
-
No change
- ND:
-
Not detected
- OPRT:
-
Orotate phosphoribosyl transferase
- PD:
-
Progressive disease
- PR:
-
Partial response
- QOL:
-
Quality of life
- RR:
-
Response ratio
References
Piccart MJ, Awada A, Hamilton, A: Integration of new therapies into management of metastatic breast cancer: A focus on chemotherapy, treatment selection through use of molecular markers, and newly developed biologic therapies in late clinical development. 35th ASCO Educational Book, pp526–539, 1999.
Henderson IC: Chemotherapy for metastatic disease. In: Harris JR, Hellmann S, Henderson IC, Kinne DW eds, Breast Diseases, 2nd ed, JB Lippincott Co, Philadelphia, pp604–665, 1991.
Stadtmauer EA, O’Neil A, Goldstein LJ, Crilley P, Mangan KF, Ingle JN, Lazarus HM, Erban J, Sickles C, Glick JH: Phase II randomized trial of high-dose chemotherapy (HDC) and stem cell support (SCT) shows no difference in overall survival or severe toxicity compared to maintenance chemotherapy with cyclophosphamide, methotorexate and 5-fluorouracil (CMF) for women with metastatic breast cancer who are responding to conventional induction chemotherapy: The Philadelphia intergroup study (PBT-1). 35thProc Am Soc Clin Oncol 18:#1a, 1999.
Regazzoni S, Pesce G, Marini G, Cavalli F, Goldhirsch A: Low-dose continuous intravenous infusion of 5-fluorouracil for metastatic breast cancer.Annal Oncol 7:807–813, 1996.
Meta-analysis group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectalcancer. J Clin Oncol 16:301–308, 1998.
Chlebowski RT, Weiner JM, Luce J, Hestorff R, Lang JE, Reynolds R, Godfrey T, Ryden VM, Bateman JR: Significance of relapse after adjuvant treatment with combination chemotherapy or 5-fluorouracil alone in high-risk breast cancer. A Western Cancer Study Group Project.Cancer Res 41:4399–4403, 1981.
Au JL, Sadee W: The pharmacology of ftorafur (R, S-1-(tetrahydro2-furanyl)-5-fluorouracil). In: Carter SK, Sakurai Y, Umezawa H eds, New drugs in cancer chemotherapy, Springer-Verlag, New York, pp100–114, 1981.
Ansfield FJ, Kallas GJ, Singson JP: Phase I-II studies of oraltegafur (ftorafur).J Clin Oncol 1:107–110, 1983.
Kajanti MJ, Pyrhonen S, Maiche AG: An oral tegafur in the treatment of metastatic breast cancer, a phase II study.EurJ Cancer 29A:863–866, 1993.
Ota K, Taguchi T, Kimura K: Report on nationwide pooled data and cohort investigation in UFT phase II study.Cancer Chemother Pharmacol 22:333–338, 1988.
Taguchi T, Terasawa T, Abe O, Yoshida Y, Tominaga T, Ogawa NA: Comparative study between 5’-DFUR and tegafur in recurrent breast cancer.Jpn J Cancer Chemoth 12:2052–2060, 1985 (in Japanese with English abstract).
Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.EurJ Cancer 34:1274–1281, 1998.
Lu ZH, Zhang R, Diasio RB: Purification and characterization of dihydropyrimidine dehydrogenase from human liver.J Biol Chem 267:17102–17109, 1992.
Diasio RB: Clinical implications of dihydropyrimidine dehydrogenase inhibition.Oncology 13 (Suppl. 3): 17–21, 1999.
Shirasaka T, Shimamoto Y, Fukushima M: Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats.Cancer Res 53:4004–4009, 1993.
Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, Saito H, Okabe H, Oyama K, Takeda S, Unemi N, Fukushima M: Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2, 4-dihydroxypyridine-lM potassium oxonate (S-l) against human colon carcinoma orthotopically implanted into nude rats.Cancer Res 56:2602–2606, 1996.
Takechi T, Nakano K, Uchida J, Mita A, Toko K, Takeda S, Unemi N, Shirasaka T: Antitumor activity and low intestinal toxicity of S-l, a new formulation of oral tegafur, in experimental tumor models in rats.Cancer Chemother Pharmacol 39:205–211, 1997.
Yoshisue K, Hironaga K, Yamaguchi S, Yamamoto A, Nagayama S, Kawaguchi Y: Reduction of 5-fluo-rouracil (5-FU) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated simultaneous administration of potassium oxonate (Oxo) in rats.Cancer Chemother Pharmacol 46:51–56, 2000.
Taguchi T, Inuyama Y, Kanamaru R, Hasegawa K, Akazawa S, Niitani H, Furue H, Kurihara M, Ota K, Suga S, Ariyoshi Y, Takai S, Shimoyama T, Toge T, Takashima S, Sugimachi K, Hara Y, Fujita H, Kimura K, Saito T, Tsukagashi S, Nakao I: Phase I study of S-l.Jpn J Cancer Chemother 24:2253–2264, 1997 (in Japanese with English abstract).
World Health Organization: WHO handbook for reporting results of cancer treatment WHO offset Publ. No.48. Geneva, World health organization, 1979.
Japan Society for Cancer Therapy: Criteria for the evaluation of the clinical effects of solid cancer chemotherapy.JJpn Soc Cancer Ther 28:101–130, 1993.
Kaplan EL, Meier P: Nonparametric estimation from incomplete observations.J Am Stat Assoc 53:457–481, 1958.
Arellano M, Malet-Martino M, Martino R, Gires P: The anti-cancer drug 5-fluorouracil is metabolized by the isolated perfused rat liver and in rats into highly toxic fluoroacetate.Br J Cancer 77:79–86, 1988.
Okeda R, Shibutani M, Matsuo T, Kuroiwa T, Shimokawa R, Tajima T: Experimental neurotoxicity of 5-fluorouracil and its derivatives is due to poisoning by the monofluorinated organic metabolites, monofluoroacetatic acid and α-fluoro-β-alanine.Acta Neuropathol 81:66–73, 1990.
Pazdur R, Lassere Y, Rhodes V, Ajani JA, Sugarman SM, Part YZ, Jones DV Jr, Markowitz AB, Abbruzzese JL, Bready B, Levin B: Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma.J Clin Oncol 12:2296–2300, 1994.
Villalon AH, De Guzman LM, Samson MC, Guancia AA, Fernando GY, Romana IB: A comparative, randomized trial of UFT and 5-fluorouracil in combination with cyclophosphamide and doxorubicin in the treatment of advanced breast cancer patients at the Philippines general hospital.Oncology 54 (Suppl. 1):2–6, 1997.
Ho DH, Pazdur R, Covington W, Brown N, Huo YY, Lassere Y, Kuritani J: Comparison of 5-Fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus Nl-(2’-tetrahydrofuryl)-5-fluorouracil.Clin Cancer Res 4:2085–2088, 1998.
Hirata K, Horikoshi N, Aiba K, Okazaki M, Denno R, Sasaki K, Nakano Y, Ishizuka H, Shirasaka T: Pharmacokinetic study of S-l, a novel oral fluorouracil antitumor drug.Clin Cancer Res 5:2002–2005, 1999.
Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T: Late phase II study of novel oral fluoropyrimidine anticancer drug S-l (IM tega-fur-0.4M gimestat-lM otastat potassium) in advanced gastric cancer patients.Eur J Cancer 34:1715–1720, 1998.
Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T: Multicenter Phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.J Clin Oncol 17:485–493, 1999.
Blum JL, Dieras V, Russo PML, Horton J, Rutman O, Buzdar A, Osterwalder B: Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients.Cancer 92:1759–1768, 2001.
Smorenburg CH, Sparreboom A, Bontenbal M, Ver-weij J: Combination chemotherapy of the taxanes and antimetabolites: its use and limitations.Eur J Cancer 37:2310–2323, 2001.
Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishit-suka H: Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts.Cancer Res 58:685–690, 1998.
Liu G, Franssen E, Fitch MI, Warner E: Patient preferences for oral versus intravenous palliative chemohtherapy.J Clin Oncol 15:110–115, 1997.
Baccanari DP, Davis ST, Knick VC, Spector T: 5-Ethynyluracil (776C85): A potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluo-rouracil.Proc Natl Acad Sei USA 90:11064–11068, 1993
Baker SD, Khor SP, Adjei AA, Doucette M, Spector T, Donehower RC, Grochow LB, Sartorius SE, Noe DA, Hohneker JA, Rowinsky EK: Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase.J Clin Oncol 14:3085–3096, 1996.
Rivera E, Sutton L, Colwell B, Graham M, Frye D, Somerville M, Conklin HS, McGuirt C, Levin J, Horto-bagyi GN: Multicenter phase II study of a 28-day regimen of orally administered eniluracil and fluorouracil in the treatment of patients with anthracycline- and taxane-resistant advanced breast cancer.J Clin Oncol 20:987–993, 2002.
Diasio RB: An evolving role for oral fluoropyrimidine drugs.J Clin Oncol 20:894–896, 2002.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Saeki, T., Takashima, S., Sano, M. et al. A phase II study of S-1 in patients with metastatic breast cancer — A Japanese trial by the S-1 cooperative study group, breast cancer working group. Breast Cancer 11, 194–202 (2004). https://doi.org/10.1007/BF02968301
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02968301